ACTICOAT™ for the Treatment of Burns and Chronic Wounds

INCLUSION CRITERIA 1. Must provide informed consent to participate in the study. 2. Eighteen (18) years of age or older. 3. Males and females. 4. Able to follow instructions and be deemed capable of completing the EQ-5D 5L Questionnaire appropriately. 5. Willing and able to make all required study visits, and provide a daytime telephone number on which they can be contacted directly. 6. Presenting with either a chronic wound or burn which is deemed suitable for treatment with ACTICOAT and meets either of the following requirements: 1. A full or partial thickness chronic (≥ 4 weeks duration) wound, consisting of a Venous Leg Ulcer, Pressure Ulcer or Diabetic Foot Ulcer, which in the opinion of the Investigator, or delegated Sub-Investigator, appears to be infected based on documented clinical signs and symptoms of infection. 2. A recently acquired (≤ 7 days) non-infected burn, comprising a full or partial thickness wound, covering a minimum 0.5% TBSA. The maximum must be less than 10% TBSA. Absence of infection will be determined by the Investigator / Sub-Investigator. EXCLUSION CRITERIA 1. Contraindications or hypersensitivity to the use of the test article, ancillary products or their components (e.g., known sensitivity to silver). 2. Participation in the treatment period of another clinical trial within thirty (30) days of Visit 1. 3. Treatment with any other silver dressing (i.e. non ACTICOAT dressing) within seven (7) days of Visit 1. 4. Patients with skin features which in the opinion of the Investigator, will interfere with the study assessments. 5. Patients requiring concomitant use of NPWT on the reference wound. 6. Patients who have participated previously in this clinical trial and who have healed or been withdrawn. 7. Patients with a history of poor compliance with medical treatment. 8. Patients who, in the opinion of the Investigator, are experiencing burn shock. 9. Patients with any other medical or physical condition that, in the opinion of the Investigator, would preclude safe subject participation in the study.